Tempus AI Inc Dossier
Qualitative Analysis
Business overview
Tempus AI, Inc. (NASDAQ: TEM) is a technology company advancing precision medicine through the practical application of artificial intelligence, including generative and agentic AI, in healthcare. The company operates a disease-agnostic platform that aggregates de-identified clinical and molecular data to develop AI-enabled diagnostics and insights for personalized patient care. Tempus operates across two primary product lines: Diagnostics, which provides next-generation sequencing (NGS) diagnostics, PCR profiling, and other anatomic and molecular pathology testing; and Data and Applications, which licenses structured multimodal data and provides software-enabled services to life sciences companies, researchers, and healthcare providers. As of mid-2026, Tempus is connected to approximately 50-55% of US oncologists and 60-65% of US academic medical centers, amassing a library of clinical and molecular data exceeding 500 petabytes.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expansion of the AI-enabled Next platform to cover six additional cancer indications, including breast, colorectal, ovarian, prostate, and urothelial cancers.
Expected impact: Enhances clinical utility and helps clinicians identify appropriate testing pathways, driving deeper adoption across community-based health systems.
Launching an open-source digital pathology consortium with founding members including Yale New Haven Health and other leading cancer centers.
Expected impact: Aims to standardize and accelerate the adoption of digital pathology workflows, feeding more multimodal data back into the Tempus AI ecosystem.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of a digital pathology leader to secure access to nearly 7 million digitized pathology slide images and associated clinical/molecular data, substantially accelerating Tempus' efforts to build the largest foundation model in oncology.
Financial impact: Paid predominantly in Tempus common stock, with Tempus assuming Paige's remaining commitments under its Microsoft Azure cloud services agreement.
Acquisition of a leader in genetic testing to expand Tempus' capabilities in inherited cancer risk and facilitate expansion into new disease categories such as pediatrics, rare disease, immunology, reproductive health, and cardiology.
Financial impact: Structured as $375 million in cash and $225 million in shares at closing, financed in part through a debt facility provided by Ares Management Credit funds.
Strategic Partnerships
Leverages AI, multimodal real-world data, and data science techniques to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs.
Terms: Terms not publicly disclosed
Provides Gilead with enterprise-wide access to Tempus' AI-driven Lens platform and dedicated analytical services to inform oncology R&D initiatives, trial design, and biomarker strategy.
Terms: Terms not publicly disclosed
A multi-faceted collaboration to integrate Tempus' molecular diagnostics into clinical workflows, automate clinical trial matching via the TIME Trial Program, and co-develop AI tools across Southern California hospitals.
Terms: Terms not publicly disclosed